Tocilizumab improves 28-day survival in hospitalized patients with severe COVID-19: an open label, prospective study.

Theodoros KarampitsakosElli MalakounidouOurania PapaioannouVasilina DimakopoulouEirini ZarkadiMatthaios KatsarasPanagiota TsiriGeorgios TsirikosVasiliki GeorgiopoulouIoanna OikonomouChristos DavoulosDimitrios VelissarisFotios SampsonasMarkos MarangosKarolina AkinosoglouArgyris Tzouvelekis

Published in: Respiratory research (2021)

< 200 was observed, improved survival and other clinical outcomes in hospitalized patients with severe COVID-19 irrespective of systemic inflammatory markers levels.

Keyphrases

coronavirus disease
sars cov
early onset
rheumatoid arthritis
free survival
respiratory syndrome coronavirus
juvenile idiopathic arthritis
rheumatoid arthritis patients